Alliance Pharma
Alliance Pharma plc, headquartered in Great Britain, is a prominent player in the pharmaceutical industry, specialising in the development and commercialisation of innovative healthcare products. Founded in 1998, the company has established a strong presence in various operational regions, including Europe and Asia, focusing on prescription medicines and over-the-counter products. With a diverse portfolio that includes unique formulations and niche therapeutic areas, Alliance Pharma is recognised for its commitment to quality and patient care. The company has achieved significant milestones, including strategic acquisitions that have bolstered its market position. Notably, Alliance Pharma has garnered accolades for its effective product range, which addresses unmet medical needs and enhances patient outcomes.
DitchCarbon Score
How does Alliance Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Alliance Pharma's score of 40 is higher than 94% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Alliance Pharma's reported carbon emissions
In 2023, Alliance Pharma reported total carbon emissions of approximately 101,050 kg CO2e, with Scope 2 emissions accounting for about 45,580 kg CO2e and Scope 3 emissions contributing around 55,470 kg CO2e. The company has set ambitious climate commitments, aiming for a 65% reduction in Scope 1 and 2 greenhouse gas emissions by 2025, using 2018 as the baseline year. Additionally, Alliance Pharma targets a 25% reduction in Scope 3 emissions by 2030. In 2020, the company’s total emissions were approximately 32,396,000 kg CO2e, with Scope 1 emissions at about 64,000 kg CO2e, Scope 2 at approximately 89,000 kg CO2e, and a significant Scope 3 total of around 32,243,000 kg CO2e. By 2021, total emissions increased to approximately 37,575,000 kg CO2e, with Scope 1 at about 2,000 kg CO2e, Scope 2 at approximately 68,000 kg CO2e, and Scope 3 emissions rising to around 37,648,000 kg CO2e. Alliance Pharma's commitment to reducing its carbon footprint reflects a proactive approach to sustainability within the pharmaceutical industry, aligning with global efforts to combat climate change.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 7,000 | 00,000 | 0,000 | 0,000 | - |
| Scope 2 | 107,000 | 00,000 | 00,000 | 00,000 | 0,000 |
| Scope 3 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Alliance Pharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
